Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
Dr. Anderson has over 7 years of experience in cancer drug discovery and early-stage research. Prior to joining Cleave in early 2012, Dr. Anderson contributed to a number of oncology-focused small molecule drug discovery programs at Genentech. During this period he led a group responsible for developing novel cellular assays to report on drug activity and mechanism of action. His group contributed key mechanistic insights into the function of clinically approved drugs targeting the MAPK pathway and apoptosis. Dr. Anderson received a PhD in cell biology and biochemistry from the University of California, San Diego in conjunction with the Salk Institute where he was awarded the Martin D. Kamen Cell Biology Thesis Prize. He earned his BS degree in Biology from the University of Pittsburgh. Dr. Anderson has authored over 20 scientific publications including several in top-tier journals.
Date: 7 September 2016, 11:00 (Wednesday, 20th week, Trinity 2016)
Venue: NDM Building, Headington OX3 7FZ
Venue Details: Seminar Room
Speaker: Dr Daniel Anderson (Cleave Biosciences)
Organising department: Ludwig Institute for Cancer Research, Oxford Branch
Organisers: Christina Woodward (Oxford Ludwig Institute, Nuffield Department of Medicine, University of Oxford), Mary Muers (Oxford Ludwig Institute, NDM Experimental Medicine), Alexandra Ward (University of Oxford, Oxford Ludwig Institute, NDM Experimental Medicine)
Organiser contact email address:
Host: Dr. John Christianson (Ludwig Cancer Research, Oxford)
Part of: Ludwig Institute Seminar Series
Booking required?: Not required
Audience: Members of the University only
Editor: Christina Woodward